Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Diabetes Mellitus, Type 2: full-pipeline trial registry
63 of 351 indexed Diabetes Mellitus, Type 2 trials are currently recruiting.
Corpus placement: #18 of 28,707 conditions by registered trial count.
351 US clinical trials · 63 currently recruiting · #18 of 28,707 conditions by registered trial count
Diabetes Mellitus, Type 2: 351 US clinical trials tracked, 63 recruiting.
Diabetes Mellitus, Type 2 is the subject of 351 registered US clinical trials on ClinicalTrials.gov, 63 of them currently open to new participants. 100 are in Phase 3-4 (later-stage) and 80 in Phase 1-2 (earlier-stage). The most active sponsor is Novo Nordisk A/S, running 48 of these trials.
Enrollment posture brief
Registry condition diabetes-mellitus-type-2
OPEN 63 | RECR 18% | LATE 100 | EARLY 80 | RANK #18 | SPON 48
Volume-matched condition peers
Nearest open-share peer: Acute Myelogenous Leukemia (18% recruiting · 39 trials)
Diabetes Mellitus, Type 2 lists 63 open slots (18% of 351 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Diabetes Mellitus, Type 2 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Diabetes Mellitus, Type 2 is recruiting below its size-band peers.
63 of 351 indexed trials (17.9%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Diabetes Mellitus, Type 2 trials is spread across many organizations.
Novo Nordisk A/S accounts for 48 of 351 trials (13.7%). 143 distinct sponsors appear on at least one study for this condition label.
-
Typical Diabetes Mellitus, Type 2 enrolment sits around 150 participants.
Median target enrolment is 150 among the 349 trials that report a genuine target (sentinel values excluded). 142 of those (40.7%) plan for fewer than 100 participants.
-
Diabetes Mellitus, Type 2 research is mostly interventional.
321 interventional and 30 observational studies make up this index (91.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
351 total, page 5 of 8
A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus
Hoffmann-La Roche
NCT00266240
Technology to Improve the Health of Resource-poor Hispanics With Diabetes
Baylor College of Medicine
NCT03394456
Evaluation of Blood Volume and Perceived Pain During Fingerstick Monitoring of Blood Glucose
Becton, Dickinson and Company
NCT00741390
A Study for Patients With Type 2 Diabetes Mellitus
Eli Lilly and Company
NCT00804986
A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight
Novo Nordisk A/S
NCT05486065
Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug
Boehringer Ingelheim
NCT00819091
Efficacy, Safety and Preference Study of a Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in Diabetics
Novo Nordisk A/S
NCT00773279
Study In Postmenopausal Women With Type 2 Diabetes Looking At Approved Diabetes Drugs And How They Affect Bone Health
GlaxoSmithKline
NCT00679939
Benefits of Insulin Supplementation for Correction of Hyperglycemia in Patients With Type 2 Diabetes
Emory University
NCT02408120
Expanding Technology-Enabled Nurse Delivered Chronic Disease Care
Duke University
NCT05120544
A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin
Janssen Research & Development
NCT02025907
Internet Intervention to Improve Rural Diabetes Care
University of Alabama at Birmingham
NCT00403091
Computerized Cognitive Training for Diabetic Elderly Veterans
VA Office of Research and Development
NCT01736124
A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Sulfonylurea Alone or Sulfonylurea Plus Metformin Therapy
Hoffmann-La Roche
NCT01691989
Improving Diabetic Patient Health Through Assistive-Reading Technology
GogyUp
NCT05337306
Study to Assess Safety and Effect of a Prebiotic Fiber Meal Replacement Shake in Individuals With Type 2 Diabetes
Uplifting Results Labs
NCT05110703
Add Glucokinase Activator to Target A1c
vTv Therapeutics
NCT02405260
Multi-Center Study Comparing Efficacy and Safety of Frequently Modified Insulin Therapy
Hygieia Research
NCT02424500
Type 2 Diabetes (T2D) Basal Insulin Users: The Mobile Study (MOBILE)
DexCom
NCT03566693
A Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (>=10 to <18 Years) With Type 2 Diabetes Mellitus
Janssen Research & Development
NCT03170518
Technology Intervention for Diabetes Engagement & Self-Care (TIDES)
Geisinger Clinic
NCT01440530
Impact of Community Health Workers on Adherence to Therapy for Non-Communicable Chronic Disease in Chiapas, Mexico
Brigham and Women's Hospital
NCT02549495
Regional Fat Depots and Insulin Resistance
Stanford University
NCT01336777
Defective Atypical Protein Kinase C (PKC) Activation in Diabetes and Metabolic Syndrome
VA Office of Research and Development
NCT00690755
Managing Type 1 and High Risk Type 2 Diabetes in the Hospital Setting: Glucose as a Vital Sign
Scripps Whittier Diabetes Institute
NCT03068273
Getting in Balance: A Workplace Diabetes Prevention Intervention Trial
Kaiser Permanente
NCT02589873
The Diabetes Medication Adherence Promotion Intervention Trial
Vanderbilt University
NCT02458495
Advanced Medical Therapy Versus Advanced Medical Therapy Plus Bariatric Surgery for the Resolution of Type 2 Diabetes
The Cleveland Clinic
NCT00432809
Evaluating a Web-Based Cardiovascular Disease Risk Factor Reduction Program Among American Indians
Black Hills Center for American Indian Health
NCT00608387
Lifestyle Intervention's Impact on Health Care Costs
University of Virginia
NCT00717158
Switching From Insulin Glargine to Insulin Degludec in Subjects With Type 2 Diabetes Mellitus (BEGIN™)
Novo Nordisk A/S
NCT01135992
SomaSignal Tests on Medical Management and Change in Risk in Patients With Diabetes
Emory University
NCT05256706
Screening, Brief Intervention, and Referral to Treatment in Primary Care
Duke University
NCT01966432
Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background Inclusive
Boehringer Ingelheim
NCT00800683
A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes
Novo Nordisk A/S
NCT04596631
A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients
Metabolic Solutions Development Company
NCT01280695
A Study of RO5095932 in Patients With Type 2 Diabetes Mellitus
Hoffmann-La Roche
NCT00961909
PF-06291874 Multiple Ascending Dose Study In Type 2 Diabetes Mellitus Patients
Pfizer
NCT01856595
Managing Diabetes to Gain Opportunities for a More Active Life
University of Chicago
NCT03692208
Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy
Sangamo Therapeutics
NCT00406458
A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)
Novo Nordisk A/S
NCT04865770
Dietary Approaches to Stop Hypertension for Diabetes
Johns Hopkins University
NCT04286555
Ticagrelor With and Without Aspirin in Patients With Diabetes Mellitus
University of Florida
NCT04484259
Delivering Health: Addressing Diabetes and Food Insecurity
University of Arkansas
NCT04831216
A Study of LC542019 in Healthy Subjects and Subjects With T2DM
LG Chem
NCT06333977
A Sub-study to LMF237A2302 to Assess the Effect of 24 Weeks Treatment With Initial Combination of Vildagliptin Plus Metformin
Novartis
NCT00468039
A Study of GSK256073 in Subjects With Type 2 Diabetes Mellitus Who Are Being Treated With Metformin
GlaxoSmithKline
NCT01376323
T2D Pilot Study for Patients With Uncontrolled Type 2 Diabetes
Duke University
NCT06988540
Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy
Sangamo Therapeutics
NCT00476931
Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females
Pfizer
NCT01301456
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 42 |
| Phase 2 | 38 |
| Phase 3 | 74 |
| Phase 4 | 26 |
Top Sponsors
Named interventions
Most-linked intervention names on Diabetes Mellitus, Type 2 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Diabetes Mellitus, Type 2 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Diabetes Mellitus, Type 2 page
351 registered trials, 63 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 63 Diabetes Mellitus, Type 2 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Novo Nordisk A/S sponsors the most Diabetes Mellitus, Type 2 trials on record, review their full trial history before evaluating a specific study. See Novo Nordisk A/S's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Diabetes Mellitus, Type 2 condition card totals 351 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.